丁丙诺啡治疗新生儿戒断综合征
在这项单中心、双盲、双模拟临床试验中,63名胎龄≥37周、有宫内阿片暴露且出现新生儿戒断综合征的足月婴儿被随机分配接受舌下丁丙诺啡或口服吗啡治疗。丁丙诺啡组的中位治疗持续时间(15天 vs 28天)和中位住院时间(21天 vs 33天)均显著短于吗啡组(两项比较 P<0.001),两组不良事件发生率相似。
要点
- 舌下丁丙诺啡组中位治疗持续时间为15天,口服吗啡组为28天,差异显著(P<0.001)。
- 丁丙诺啡组中位住院时间为21天,吗啡组为33天,差异显著(P<0.001)。
- 两组不良事件发生率相似,辅助苯巴比妥使用比例无显著差异(P=0.36)。
核心结论
- 在新生儿戒断综合征婴儿中,舌下丁丙诺啡治疗较口服吗啡治疗导致更短的治疗持续时间和更短的住院时间,且不良事件发生率相似。
研究设计与样本
- 单中心、双盲、双模拟临床试验,随机分配63名胎龄≥37周、有宫内阿片暴露且出现新生儿戒断综合征体征的足月婴儿接受舌下丁丙诺啡或口服吗啡治疗。
- 症状未能在最大剂量阿片类药物下控制的婴儿接受辅助苯巴比妥治疗。
- 主要终点为新生儿阿片戒断症状的治疗持续时间;次要临床终点为住院时间、需要辅助苯巴比妥治疗的婴儿百分比及安全性。
主要发现
- 丁丙诺啡组中位治疗持续时间为15天,吗啡组为28天(P<0.001)。
- 丁丙诺啡组中位住院时间为21天,吗啡组为33天(P<0.001)。
- 辅助苯巴比妥使用:丁丙诺啡组33名婴儿中5名(15%),吗啡组30名婴儿中7名(23%)(P=0.36)。
- 两组不良事件发生率相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication. METHODS: In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (≥37 weeks of gestation) who had been exposed to opioids in utero and who had signs of the neonatal abstinence syndrome to receive either sublingual buprenorphine or oral morphine. Infants with symptoms that were not controlled with the maximum dose of opioid were treated with adjunctive phenobarbital. The primary end point was the duration of treatment for symptoms of neonatal opioid withdrawal. Secondary clinical end points were the length of hospital stay, the percentage of infants who required supplemental treatment with phenobarbital, and safety. RESULTS: The median duration of treatment was significantly shorter with buprenorphine than with morphine (15 days vs. 28 days), as was the median length of hospital stay (21 days vs. 33 days) (P<0.001 for both comparisons). Adjunctive phenobarbital was administered in 5 of 33 infants (15%) in the buprenorphine group and in 7 of 30 infants (23%) in the morphine group (P=0.36). Rates of adverse events were similar in the two groups. CONCLUSIONS: Among infants with the neonatal abstinence syndrome, treatment with sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than treatment with oral morphine, with similar rates of adverse events. (Funded by the National Institute on Drug Abuse; BBORN ClinicalTrials.gov number, NCT01452789 .).
引用
- Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med. 2017. PMID: 28468518. doi:10.1056/NEJMoa1614835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。